drugset / Trial / NCT05507632
Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of Donafenib plus Sintilimab in combination with transarterial chemoembolisation (TACE) in patients with unresectable hepatocellular carcinoma(HCC).
Timeline
- Start
- 2022-08-18
- Primary completion
- 2026-03-26
- Completion
- 2026-12-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Donafenib | Small molecule | — | — |
| Subject | Sintilimab | Monoclonal antibody | — | — |